GlaxoSmithKline makes $300m investment in 23andMe, forms 50-50 R&D pact

Under a new 4-year agreement, 23andMe and GlaxoSmithKline (GSK) will jointly form preclinical programs leveraging 23andMe's genotypic and phenotypic data. GlaxoSmithKline has made a $300 million equity investment in 23andMe as part of the deal.

Under a new 4-year agreement, 23andMe and GlaxoSmithKline (GSK) will jointly form preclinical programs leveraging 23andMe's genotypic and phenotypic data. GlaxoSmithKline has made a $300 million equity investment in 23andMe as part of the deal. GSK and 23andMe seek to bring existing programs into the collaboration, including 23andMe's early-stage programs and GSK's LRRK2 inhibitor. GSK believes that 23andMe's database of people who know about their LRRK2 variant status will help the Parkinson's program enroll patients prior to the clinical proof of concept stage. The two companies also intend to use 23andMe's data to jointly discover drug targets, which each entity allowed to advance independently as well. The partners will divide the costs and profits related to these activities. The new deal also includes an option to extend the collaboration into a 5th year, in which case GSK would become 23andMe's exclusive drug target discovery collaborator.